AIM ImmunoTech Inc. — Director's Dealing 2018

Dec 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-11-30

Reporting Person: EQUELS THOMAS K. (Director, Exec. Vice Chairman/CEO/Pres.)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-30	Common Stock	P	1354	$0.1891	Acquired	779661	Direct
2018-11-30	Common Stock	P	5	$0.1892	Acquired	779666	Direct
2018-11-30	Common Stock	P	9557	$0.19	Acquired	789223	Direct
2018-11-30	Common Stock	P	2400	$0.193	Acquired	791623	Direct
2018-11-30	Common Stock	P	50	$0.1938	Acquired	791673	Direct
2018-11-30	Common Stock	P	300	$0.1944	Acquired	791973	Direct
2018-11-30	Common Stock	P	334	$0.1945	Acquired	792307	Direct
2018-11-30	Common Stock	P	6000	$0.196	Acquired	798307	Direct